Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
0.00 (0.00%)
Jul 10 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range     -
52 week 56.50 - 136.00
Open     -
Vol / Avg. 0.00/63,250.00
Mkt cap 3.06B
P/E     -
Div/yield     -
EPS -0.45
Shares 26.11M
Beta     -
Inst. own     -
Aug 28, 2014
Half Year 2014 Bavarian Nordic A/S Earnings Release Add to calendar
Jun 26, 2014
Bavarian Nordic A/S at CF&B European Midcap Event "Spring" Conference
Jun 19, 2014
Bavarian Nordic A/S at Citi European Healthcare Conference
Jun 5, 2014
Bavarian Nordic A/S at Jefferies Global Healthcare Conference
Jun 1, 2014
Bavarian Nordic A/S PROSTVAC Update and Reception
May 14, 2014
Q1 2014 Bavarian Nordic A/S Earnings Conference Call
May 14, 2014
Q1 2014 Bavarian Nordic A/S Earnings Release
Apr 24, 2014
Bavarian Nordic A/S Annual General Meeting

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 0.42% -3.85%
Operating margin 1.19% 2.76%
EBITD margin - 6.37%
Return on average assets 0.35% -3.12%
Return on average equity 0.49% -4.73%
Employees 426 -
CDP Score - -


Hejreskovvej 10A

Website links


Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines� pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC and MVA-BN PRO; two projects in breast cancer, CV-301 and MVA-BN HER2; one project in lung cancer, CV-301 lung, and one project in ovarian cancer, CV-301 ovarian. The Infectious Disease�s pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate; an anthrax vaccine candidate, MVA-BN Anthrax, and a RSV vaccine candidate, MVA-BN RSV. Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany.

Officers and directors

Gerard W. M. van Odijk M.D. Chairman of the Board
Age: 57
Paul Chaplin Ph.D. President, Chief Executive Officer
Age: 47
Anders Gersel Pedersen M.D. Deputy Chairman of the Board
Age: 63
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 48
James B. Breitmeyer Executive Vice President, Division President of Cancer Vaccine
Peter Kurstein Director
Age: 57
Claus Braestrup Independent Director
Age: 69
Erik Gregers Hansen Independent Director
Age: 61